Table 3 Comparison of primary outcomes.

From: Safety and efficacy of N-acetylcysteine (NAC) as an adjunct to standard treatment in patients with acute ischemic stroke: a randomized controlled pilot trial (NACTLYS)

Total (N = 40)

TPA (N = 21)

TPA + NAC (N = 19)

P value

Effect size (95% CI)

Any ICH (including SICH)

0

2 (10.53%)

0.21

− 10.5 (− 24.3 to 3.27)

SICH

0

1 (5.26%)

0.47

− 5.1 (− 15.3 to 4.77)

Extracranial bleeding

 Mild

0

2 (10.53%)

0.21

− 10.5 (− 24.3 to 3.27)

 Moderate

0

0

 Major

0

0

Adverse reactions

 Vomiting

1 (4.76%)

0

0.99

− 5.2(− 15.3 to 4.77)

 Itching

0

1 (5.26%)

  1. ICH Intracerebral Hemorrhage; SICH Symptomatic intracerebral hemorrhage.